Detection of circulating tumor DNA in early- and late-stage human malignancies

Science Translational Medicine

Volumn 6, Issue 224, 2014, Pages

  Bettegowda, Chetan ^a,b   Sausen, Mark ^a,w   Leary, Rebecca J ^a,x   Kinde, Isaac ^a   Wang, Yuxuan ^a   Agrawal, Nishant ^a,b   Bartlett, Bjarne R ^a,c   Wang, Hao ^a   Luber, Brandon ^a   Alani, Rhoda M ^d   Antonarakis, Emmanuel S ^a   Azad, Nilofer S ^a   Bardelli, Alberto ^e,f,g   Brem, Henry ^b   Cameron, John L ^b   Lee, Clarence C ^h   Fecher, Leslie A ^i,j   Gallia, Gary L ^b   Gibbs, Peter ^k,l   Le, Dung ^a,c   Giuntoli, Robert L ^b   Goggins, Michael ^b   Hogarty, Michael D ^m   Holdhoff, Matthias ^a   Hong, Seung Mo ^b,n   Jiao, Yuchen ^a   Juhl, Hartmut H ^o   Kim, Jenny J ^a   Siravegna, Giulia ^p   Laheru, Daniel A ^a   Lauricella, Calogero ^p   Lim, Michael ^b   Lipson, Evan J ^a   Marie, Suely Kazue Nagahashi ^q   Netto, George J ^b   Oliner, Kelly S ^r   Olivi, Alessandro ^b   Olsson, Louise ^s   Riggins, Gregory J ^b   Sartore Bianchi, Andrea ^p   Schmidt, Kerstin ^a   Shih, Ie Ming ^b   Oba Shinjo, Sueli Mieko ^q   Siena, Salvatore ^p   Theodorescu, Dan ^t   Tie, Jeanne ^k   Harkins, Timothy T ^h   Veronese, Silvio ^p   Wang, Tian Li ^b   Weingart, Jon D ^b   Wolfgang, Christopher L ^b   Wood, Laura D ^b   Xing, Dongmei ^b   Hruban, Ralph H ^b   Wu, Jian ^a,u,y   Allen, Peter J ^v   Schmidt, C Max ⁱ   Choti, Michael A ^b,z   Velculescu, Victor E ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a   Papadopoulos, Nickolas ^a   Diaz Jr , Luis A ^a,c   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Depts of Surg Medicine Pathol Obstet and Gynecol Otolaryngology and Neurosurg at Johns H   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^h Life Technologies Corporation   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

^j INDIANA UNIVERSITY HEALTH   (United States)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

^l WESTERN HOSPITAL   (Australia)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ University of Ulsan College of Medicine   (South Korea)

^o Indivumed GmbH   (Germany)

^p OSPEDALE NIGUARDA CA GRANDA   (Italy)

^q UNIVERSITY OF SÃO PAULO   (Brazil)

^r AMGEN INC   (United States)

^s KAROLINSKA INSTITUTE   (Sweden)

^t UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^u MyGenostics Inc   (United States)

^v MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^w Personal Genome Diagnostics   (United States)

^x NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^y FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^z UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST ADENOCARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CIRCULATING TUMOR CELL; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC COLORECTAL CANCER; ONCOGENE K RAS; OVARY CANCER; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; THYROID CANCER; TUMOR LOCALIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; YOUNG ADULT;

EID: 84896371874     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007094     Document Type: Article

References (58)

1. American Cancer Society, Cancer Facts and Figures 2012 (American Cancer Society, Atlanta, GA, 2012).
2. R. Mazzucchelli, P. Colanzi, R. Pomante, G. Muzzonigro, R. Montironi, Prostate tissue and serum markers. Adv. Clin. Pathol. 4, 111-120 (2000).
3. A. Ruibal Morell, CEA serum levels in non-neoplastic disease. Int. J. Biol. Markers 7, 160-166 (1992).
4. K. A. Sikaris, CA125 - A test with a change of heart. Heart Lung Circ. 20, 634-640 (2011).
5. U. K. Ballehaninna, R. S. Chamberlain, Serum CA 19-9 as a biomarker for pancreatic cancer - A comprehensive review. Indian J. Surg. Oncol. 2, 88-100 (2011).
6. H. J. Wanebo, B. Rao, C. M. Pinsky, R. G. Hoffman, M. Stearns, M. K. Schwartz, H. F. Oettgen, Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N. Engl. J. Med. 299, 448-451 (1978).
7. L. R. Yates, P. J. Campbell, Evolution of the cancer genome. Nat. Rev. Genet. 13, 795-806 (2012).
8. M. Meyerson, S. Gabriel, G. Getz, Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685-696 (2010).
9. B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr., K. W. Kinzler, Cancer genome landscapes. Science 339, 1546-1558 (2013).
10. M. R. Stratton, Exploring the genomes of cancer cells: Progress and promise. Science 331, 1553-1558 (2011).
11. E. R. Mardis, Genome sequencing and cancer. Curr. Opin. Genet. Dev. 22, 245-250 (2012).
12. M. Fleischhacker, B. Schmidt, Circulating nucleic acids (CNAs) and cancer - A survey. Biochim. Biophys. Acta 1775, 181-232 (2007).
13. C. Alix-Panabières, H. Schwarzenbach, K. Pantel, Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 63, 199-215 (2012).
14. M. Stroun, J. Lyautey, C. Lederrey, A. Olson-Sand, P. Anker, About the possible origin and mechanism of circulating DNA: Apoptosis and active DNA release. Clin. Chim. Acta 313, 139-142 (2001).
15. E. Racila, D. Euhus, A. J. Weiss, C. Rao, J. McConnell, L. W. Terstappen, J. W. Uhr, Detection and characterization of carcinoma cells in the blood. Proc. Natl. Acad. Sci. U.S.A. 95, 4589-4594 (1998).
16. S. J. Dawson, D. W. Tsui, M. Murtaza, H. Biggs, O. M. Rueda, S. F. Chin, M. J. Dunning, D. Gale, T. Forshew, B. Mahler-Araujo, S. Rajan, S. Humphray, J. Becq, D. Halsall, M. Wallis, D. Bentley, C. Caldas, N. Rosenfeld, Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
17. S. Maheswaran, L. V. Sequist, S. Nagrath, L. Ulkus, B. Brannigan, C. V. Collura, E. Inserra, S. Diederichs, A. J. Iafrate, D. W. Bell, S. Digumarthy, A. Muzikansky, D. Irimia, J. Settleman, R. G. Tompkins, T. J. Lynch, M. Toner, D. A. Haber, Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008).
18. E. A. Punnoose, S. Atwal, W. Liu, R. Raja, B. M. Fine, B. G. Hughes, R. J. Hicks, G. M. Hampton, L. C. Amler, A. Pirzkall, M. R. Lackner, Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 18, 2391-2401 (2012).
19. M. Sausen, R. J. Leary, S. Jones, J. Wu, C. P. Reynolds, X. Liu, A. Blackford, G. Parmigiani, L. A. Diaz Jr., N. Papadopoulos, B. Vogelstein, K. W. Kinzler, V. E. Velculescu, M. D. Hogarty, Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 45, 12-17 (2013).
20. L. A. Diaz Jr., R. T. Williams, J. Wu, I. Kinde, J. R. Hecht, J. Berlin, B. Allen, I. Bozic, J. G. Reiter, M. A. Nowak, K. W. Kinzler, K. S. Oliner, B. Vogelstein, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
21. F. Diehl, K. Schmidt, M. A. Choti, K. Romans, S. Goodman, M. Li, K. Thornton, N. Agrawal, L. Sokoll, S. A. Szabo, K. W. Kinzler, B. Vogelstein, L. A. Diaz Jr., Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985-990 (2008).
22. T. Forshew, M. Murtaza, C. Parkinson, D. Gale, D. W. Tsui, F. Kaper, S. J. Dawson, A. M. Piskorz, M. Jimenez-Linan, D. Bentley, J. Hadfield, A. P. May, C. Caldas, J. D. Brenton, N. Rosenfeld, Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 4, 136ra68 (2012).
23. M. Murtaza, S. J. Dawson, D. W. Tsui, D. Gale, T. Forshew, A. M. Piskorz, C. Parkinson, S. F. Chin, Z. Kingsbury, A. S. Wong, F. Marass, S. Humphray, J. Hadfield, D. Bentley, T. M. Chin, J. D. Brenton, C. Caldas, N. Rosenfeld, Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013).
24. Y. Kuang, A. Rogers, B. Y. Yeap, L. Wang, M. Makrigiorgos, K. Vetrand, S. Thiede, R. J. Distel, P. A. Jänne, Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin. Cancer Res. 15, 2630-2636 (2009).
25. K. Taniguchi, J. Uchida, K. Nishino, T. Kumagai, T.Okuyama, J. Okami, M. Higashiyama, K. Kodama, F. Imamura, K. Kato, Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin. Cancer Res. 17, 7808-7815 (2011).
26. H. W. Chang, S. M. Lee, S. N. Goodman, G. Singer, S. K. Cho, L. J. Sokoll, F. J. Montz, R. Roden, Z. Zhang, D. W. Chan, R. J. Kurman, I. e. M. Shih, Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J. Natl. Cancer Inst. 94, 1697-1703 (2002).
27. M. Holdhoff, K. Schmidt, R. Donehower, L. A. Diaz Jr., Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J. Natl. Cancer Inst. 101, 1284-1285 (2009).
28. L. A. Diaz Jr., M. Sausen, G. A. Fisher, V. E. Velculescu, Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget 4, 1856-1857 (2013).
29. C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, T. J. Price, L. Shepherd, H. J. Au, C. Langer, M. J. Moore, J. R. Zalcberg, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
30. S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, E. Valtorta, R. Schiavo, M. Buscarino, G. Siravegna, K. Bencardino, A. Cercek, C. T. Chen, S. Veronese, C. Zanon, A. Sartore-Bianchi, M. Gambacorta, M. Gallicchio, E. Vakiani, V. Boscaro, E. Medico, M. Weiser, S. Siena, F. Di Nicolantonio, D. Solit, A. Bardelli, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
31. F. Di Nicolantonio, M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, A. Bardelli, Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).
32. F. Loupakis, A. Ruzzo, C. Cremolini, B. Vincenzi, L. Salvatore, D. Santini, G. Masi, I. Stasi, E. Canestrari, E. Rulli, I. Floriani, K. Bencardino, N. Galluccio, V. Catalano, G. Tonini, M. Magnani, G. Fontanini, F. Basolo, A. Falcone, F. Graziano, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 101, 715-721 (2009).
33. M. Peeters, K. S. Oliner, A. Parker, S. Siena, E. Van Cutsem, J. Huang, Y. Humblet, J. L. Van Laethem, T. André, J. Wiezorek, D. Reese, S. D. Patterson, Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin. Cancer Res. 19, 1902-1912 (2013).
34. C. Montagut, A. Dalmases, B. Bellosillo, M. Crespo, S. Pairet, M. Iglesias, M. Salido, M. Gallen, S. Marsters, S. P. Tsai, A. Minoche, S. Seshagiri, S. Serrano, H. Himmelbauer, J. Bellmunt, A. Rovira, J. Settleman, F. Bosch, J. Albanell, Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 18, 221-223 (2012).
35. D. Tougeron, U. Cortes, A. Ferru, C. Villalva, C. Silvain, J. M. Tourani, P. Levillain, L. Karayan-Tapon, Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother. Pharmacol. 72, 397-403 (2013).
36. Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak, S. Szabo, H. Yan, A. Gazdar, S. M. Powell, G. J. Riggins, J. K. Willson, S. Markowitz, K. W. Kinzler, B. Vogelstein, V. E. Velculescu, High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
37. M. J. Duffy, Clinical uses of tumor markers: A critical review. Crit. Rev. Clin. Lab. Sci. 38, 225-262 (2001).
38. L. B. Saltz, Biomarkers in colorectal cancer: Added value or just added expense? Expert Rev. Mol. Diagn. 8, 231-233 (2008).
39. C. L. Sawyers, The cancer biomarker problem. Nature 452, 548-552 (2008).
40. I. Kinde, J. Wu, N. Papadopoulos, K. W. Kinzler, B. Vogelstein, Detection and quantification of rare mutations with massively parallel sequencing. Proc. Natl. Acad. Sci. U.S.A. 108, 9530-9535 (2011).
41. M. Li, F. Diehl, D. Dressman, B. Vogelstein, K. W. Kinzler, BEAMing up for detection and quantification of rare sequence variants. Nat. Methods 3, 95-97 (2006).
42. R. J. Leary, I. Kinde, F. Diehl, K. Schmidt, C. Clouser, C. Duncan, A. Antipova, C. Lee, K. McKernan, F. M. De La Vega, K. W. Kinzler, B. Vogelstein, L. A. Diaz Jr., V. E. Velculescu, Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2, 20ra14 (2010).
43. S. L. Stott, C. H. Hsu, D. I. Tsukrov, M. Yu, D. T. Miyamoto, B. A. Waltman, S. M. Rothenberg, A. M. Shah, M. E. Smas, G. K. Korir, F. P. Floyd Jr., A. J. Gilman, J. B. Lord, D.Winokur, S. Springer, D. Irimia, S. Nagrath, L. V. Sequist, R. J. Lee, K. J. Isselbacher, S. Maheswaran, D. A. Haber, M. Toner, Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. U.S.A. 107, 18392-18397 (2010).
44. C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, M. Perucho, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554 (1988).
45. J. D. Brooks, Translational genomics: The challenge of developing cancer biomarkers. Genome Res. 22, 183-187 (2012).
46. F. Diehl, M. Li, D. Dressman, Y. He, D. Shen, S. Szabo, L. A. Diaz Jr., S. N. Goodman, K. A. David, H. Juhl, K. W. Kinzler, B. Vogelstein, Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl. Acad. Sci. U.S.A. 102, 16368-16373 (2005).
47. W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, K. T. Kalogeras, V. Kotoula, D. Papamichael, P. Laurent-Puig, F. Penault-Llorca, P. Rougier, B. Vincenzi, D. Santini, G. Tonini, F. Cappuzzo, M. Frattini, F. Molinari, P. Saletti, S. De Dosso, M. Martini, A. Bardelli, S. Siena, A. Sartore-Bianchi, J. Tabernero, T. Macarulla, F. Di Fiore, A. O. Gangloff, F. Ciardiello, P. Pfeiffer, C. Qvortrup, T. P. Hansen, E. Van Cutsem, H. Piessevaux, D. Lambrechts, M. Delorenzi, S. Tejpar, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
48. S. Misale, S. Arena, S. Lamba,G. Siravegna, A. Lallo, S. Hobor,M. Russo, M. Buscarino, L. Lazzari, A. S. Bianchi, K. Bencardino, A. Amatu, C. Lauricella, E. Valtorta, S. Siena, F. Di Nicolantonio, A. Bardelli, Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra26 (2014).
49. C. P. Vaughn, S. D. Zobell, L. V. Furtado, C. L. Baker, W. S. Samowitz, Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50, 307-312 (2011).
50. J. Y. Douillard, K. S. Oliner, S. Siena, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocákova, P. Ruff, M. Błasińska-Morawiec, M. Šmakal, J. L. Canon, M. Rother, R. Williams, A. Rong, J. Wiezorek, R. Sidhu, S. D. Patterson, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
51. F. C. Bidard, T. Fehm, M. Ignatiadis, J. B. Smerage, C. Alix-Panabières, W. Janni, C. Messina, C. Paoletti, V. Müller, D. F. Hayes, M. Piccart, J. Y. Pierga, Clinical application of circulating tumor cells in breast cancer: Overview of the current interventional trials. Cancer Metastasis Rev. 32, 179-188 (2013).
52. R. J. Leary, M. Sausen, I. Kinde, N. Papadopoulos, J. D. Carpten, D. Craig, J. O'Shaughnessy, K. W. Kinzler, G. Parmigiani, B. Vogelstein, L. A. Diaz Jr., V. E. Velculescu, Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci. Transl. Med. 4, 162ra154 (2012).
53. J. Wu, H. Matthaei, A. Maitra, M. Dal Molin, L. D. Wood, J. R. Eshleman, M. Goggins, M. I. Canto, R. D. Schulick, B. H. Edil, C. L.Wolfgang, A. P. Klein, L. A. Diaz Jr., P. J. Allen, C. M. Schmidt, K. W. Kinzler, N. Papadopoulos, R. H. Hruban, B. Vogelstein, Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci. Transl. Med. 3, 92ra66 (2011).
54. C. Rago, D. L. Huso, F. Diehl, B. Karim, G. Liu, N. Papadopoulos, Y. Samuels, V. E. Velculescu, B. Vogelstein, K. W. Kinzler, L. A. Diaz Jr., Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res. 67, 9364-9370 (2007).
55. S. Jones, X. Zhang, D. W. Parsons, J. C. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, S. M. Hong, B. Fu, M. T. Lin, E. S. Calhoun, M. Kamiyama, K. Walter, T. Nikolskaya, Y. Nikolsky, J. Hartigan, D. R. Smith, M. Hidalgo, S. D. Leach, A. P. Klein, E. M. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-Donahue, J. R. Eshleman, S. E. Kern, R. H. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. E. Velculescu, K. W. Kinzler, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
56. C. Bettegowda, N. Agrawal, Y. Jiao, M. Sausen, L. D. Wood, R. H. Hruban, F. J. Rodriguez, D. P. Cahill, R. McLendon, G. Riggins, V. E. Velculescu, S. M. Oba-Shinjo, S. K. Marie, B. Vogelstein, D. Bigner, H. Yan, N. Papadopoulos, K. W. Kinzler, Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333, 1453-1455 (2011).
57. C. Bettegowda, N. Agrawal, Y. Jiao, Y. Wang, L. D. Wood, F. J. Rodriguez, R. H. Hruban, G. L. Gallia, Z. A. Binder, C. J. Riggins, V. Salmasi, G. J. Riggins, Z. J. Reitman, A. Rasheed, S. Keir, S. Shinjo, S. Marie, R. McLendon, G. Jallo, B. Vogelstein, D. Bigner, H. Yan, K. W. Kinzler, N. Papadopoulos, Exomic sequencing of four rare central nervous system tumor types. Oncotarget 4, 572-583 (2013).
58. D. Dressman, H. Yan, G. Traverso, K. W. Kinzler, B. Vogelstein, Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl. Acad. Sci. U.S.A. 100, 8817-8822 (2003).